Butabarbital decreases outcomes of sufentanil SL by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of CYP3A4 inducers may well minimize sufentanil ranges and efficacy, perhaps precipitating withdrawal syndrome in clients that have produced physical dependence to sufentanil. Discontinuation of concomitantly employed CYP3A4 induce... https://saulr000uoj5.thecomputerwiki.com/user